Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
In this study, we investigated the therapeutic effect of suppression of lymphatic invasion by regulating epithelial-mesenchymal transition (EMT) in gastric cancer. Clinicopathological study using gastric cancer specimen revealed that patients with HOXB9 expression have higher node metastasis and vascular/lymphovascular infiltration. HOXB9 positive group had worse overall survival, as well. We established a gastric cancer cell line TMK-1 with HOXB9 gene and showed higher level of lymphangiogenic factors using RT-PCR. HOXB9 would be a promising molecule which could suppress the gastric cancer progression in the aspect of lymphatic invasion.
|